Published in Surg Today on September 09, 2012
Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. Br J Cancer (2015) 1.13
Predicting the response to preoperative radiation or chemoradiation by a microarray analysis of the gene expression profiles in rectal cancer. Surg Today (2012) 1.02
An update on microRNAs as colorectal cancer biomarkers: where are we and what's next? Expert Rev Mol Diagn (2014) 0.87
Sub-classification of Stage II colorectal cancer based on clinicopathological risk factors for recurrence. Surg Today (2013) 0.80
Single Nucleotide Polymorphisms as Prognostic and Predictive Factors of Adjuvant Chemotherapy in Colorectal Cancer of Stages I and II. Gastroenterol Res Pract (2016) 0.79
Impact of surgical extent and sex on the hepatic metastasis of colon cancer. Surg Today (2013) 0.79
Integrated transcriptional profiling and genomic analyses reveal RPN2 and HMGB1 as promising biomarkers in colorectal cancer. Cell Biosci (2015) 0.77
Surfing the p53 network. Nature (2000) 35.36
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
Genetic alterations during colorectal-tumor development. N Engl J Med (1988) 26.82
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol (2008) 20.89
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51
Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 12.64
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA (2008) 12.26
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol (2008) 11.73
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet (2007) 9.23
Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med (2000) 8.68
Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol (2005) 8.15
American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol (2004) 7.16
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol (2009) 7.04
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol (2010) 6.87
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut (2008) 6.26
Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst (2001) 5.68
Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol (2011) 5.63
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med (2001) 5.22
Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med (1994) 5.12
Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol (2004) 5.12
Micrometastases and survival in stage II colorectal cancer. N Engl J Med (1998) 5.11
Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst (1998) 4.65
Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J Clin Oncol (2011) 4.48
NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw (2009) 4.41
Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology (2009) 4.08
In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol (2009) 3.97
BRAF mutation in metastatic colorectal cancer. N Engl J Med (2009) 3.68
Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst (1999) 3.46
Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol (2010) 3.30
The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer (2003) 3.21
Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol (2010) 3.19
Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol (2004) 2.95
Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol (2005) 2.88
Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev (2008) 2.60
Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol (2006) 2.49
CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol (2009) 2.47
Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol (2005) 2.41
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res (2008) 2.32
Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet (1995) 2.15
Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct (1995) 2.05
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res (2009) 2.02
Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis (2003) 1.98
Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer. Gastroenterology (1998) 1.90
Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer. Clin Cancer Res (2007) 1.89
A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics (2004) 1.88
Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol (2003) 1.87
Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol (2006) 1.85
P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer (2005) 1.83
Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist (2010) 1.72
Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology (1998) 1.69
Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol (2010) 1.69
Retracted A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A (2008) 1.69
Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. Clin Cancer Res (1998) 1.68
Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res (2009) 1.67
Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol (2006) 1.62
Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res (2003) 1.53
Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology. Gut (2007) 1.47
Comparative detection of lymph node micrometastases of stage II colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry. J Clin Oncol (2002) 1.36
Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol (1998) 1.33
Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol (2000) 1.33
A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer (2005) 1.31
Molecular staging of early colon cancer on the basis of sentinel node analysis: a multicenter phase II trial. J Clin Oncol (2001) 1.26
Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer (2002) 1.24
Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. JAMA (2009) 1.21
Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann Oncol (2006) 1.18
Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer. J Mol Diagn (2008) 1.17
Prognostic significance of cytokeratin-20 reverse transcriptase polymerase chain reaction in lymph nodes of node-negative colorectal cancer patients. J Clin Oncol (2002) 1.16
Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection. Ann Surg (2007) 1.09
A gene signature of 8 genes could identify the risk of recurrence and progression in Dukes' B colon cancer patients. Oncol Rep (2007) 1.09
A multivariate analysis of adhesion molecules expression in assessment of colorectal cancer. J Surg Oncol (2007) 1.08
Quantification of colorectal cancer micrometastases in lymph nodes by nested and real-time reverse transcriptase-PCR analysis for carcinoembryonic antigen. Clin Cancer Res (2004) 1.06
Increased detection of circulating tumor cells in the blood of colorectal carcinoma patients using two reverse transcription-PCR assays and multiple blood samples. Clin Cancer Res (1999) 1.03
Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics (2008) 0.98
Molecular detection of neoplastic cells in lymph nodes of metastatic colorectal cancer patients predicts recurrence. Clin Cancer Res (1999) 0.97
Association between recurrence of sporadic colorectal cancer, high level of microsatellite instability, and loss of heterozygosity at chromosome 18q. Dis Colon Rectum (2004) 0.96
Loss of heterozygosity: an independent prognostic factor of colorectal cancer. World J Gastroenterol (2005) 0.94
Molecular prognostic markers in locally advanced colon cancer. Clin Colorectal Cancer (2007) 0.94
Prognostic impact of hematogenous tumor cell dissemination in patients with stage II colorectal cancer. Int J Cancer (2006) 0.91
Should Dukes' B patients receive adjuvant therapy? A statistical perspective. Semin Oncol (2001) 0.89
CpG-island methylation of the ER promoter in colorectal cancer: analysis of micrometastases in lymph nodes from UICC stage I and II patients. Br J Cancer (2009) 0.89
Tenascin C and epidermal growth factor receptor as markers of circulating tumoral cells in bladder and colon cancer. Oncol Rep (2005) 0.86
Evidence for colorectal cancer micrometastases using reverse transcriptase-polymerase chain reaction analysis of MUC2 in lymph nodes. Cancer Detect Prev (2000) 0.83
DNA methylation of retrotransposon genes is regulated by Piwi family members MILI and MIWI2 in murine fetal testes. Genes Dev (2008) 5.58
Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J Clin Oncol (2011) 4.48
The mechanism selecting the guide strand from small RNA duplexes is different among argonaute proteins. Plant Cell Physiol (2008) 3.15
Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med (2008) 3.15
Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study. J Gastroenterol (2004) 2.88
Dynamic stage-specific changes in imprinted differentially methylated regions during early mammalian development and prevalence of non-CpG methylation in oocytes. Development (2011) 2.28
Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology (2011) 1.96
Epigallocatechin gallate, the main component of tea polyphenol, binds to CD4 and interferes with gp120 binding. J Allergy Clin Immunol (2003) 1.87
Prognosis and risk factors of metastasis in colorectal carcinoids: results of a nationwide registry over 15 years. Gut (2007) 1.87
MVH in piRNA processing and gene silencing of retrotransposons. Genes Dev (2010) 1.84
Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res (2003) 1.83
Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients. Clin Transl Oncol (2011) 1.52
Pelvic dimensions as a predictor of difficulty in laparoscopic surgery for rectal cancer. Surg Endosc (2011) 1.51
Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer. Lab Invest (2004) 1.49
Detection of cancer cells in mesenteric vein and peripheral vessels by measuring telomerase activity in patients with colorectal cancer. Surgery (2003) 1.45
Prognostic factors for myasthenic crisis after transsternal thymectomy in patients with myasthenia gravis. J Thorac Cardiovasc Surg (2004) 1.44
Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer. Int J Oncol (2004) 1.42
The relationship of lymph node evaluation and colorectal cancer survival after curative resection: a multi-institutional study. Ann Surg Oncol (2012) 1.42
Is CD133 mRNA expression a prognostic factor in colorectal cancer? J Surg Oncol (2011) 1.41
Poor Prognosis in Critical Limb Ischemia Without Pre-Onset Intermittent Claudication. Circ J (2015) 1.40
Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Mod Pathol (2004) 1.40
Elective colon and rectal surgery differ in risk factors for wound infection: results of prospective surveillance. Ann Surg (2006) 1.39
Current status in the occurrence of postoperative bleeding, perforation and residual/local recurrence during colonoscopic treatment in Japan. Dig Endosc (2010) 1.38
JGES guidelines for colorectal endoscopic submucosal dissection/endoscopic mucosal resection. Dig Endosc (2015) 1.35
Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers. Cancer Res (2006) 1.32
A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer (2013) 1.31
Results of a Japanese nationwide multi-institutional study on lateral pelvic lymph node metastasis in low rectal cancer: is it regional or distant disease? Ann Surg (2012) 1.31
Risk factors for anastomotic leakage after surgery for colorectal cancer: results of prospective surveillance. J Am Coll Surg (2006) 1.30
Polyacrylamide gel containing egg white as new model for irradiation experiments using focused ultrasound. Ultrasound Med Biol (2004) 1.30
The Yb body, a major site for Piwi-associated RNA biogenesis and a gateway for Piwi expression and transport to the nucleus in somatic cells. J Biol Chem (2010) 1.30
Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res (2013) 1.29
Small RNA class transition from siRNA/piRNA to miRNA during pre-implantation mouse development. Nucleic Acids Res (2010) 1.27
Chromosomal instability (CIN) phenotype, CIN high or CIN low, predicts survival for colorectal cancer. J Clin Oncol (2012) 1.17
Colon cancer complicated by vascular and intestinal anomaly. Hepatogastroenterology (2004) 1.14
Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup? Int J Clin Oncol (2008) 1.13
Factors associated with technical difficulties and adverse events of colorectal endoscopic submucosal dissection: retrospective exploratory factor analysis of a multicenter prospective cohort. Int J Colorectal Dis (2014) 1.13
Use of a microbubble agent to increase the effects of high intensity focused ultrasound on liver tissue. Eur Radiol (2005) 1.13
Epigallocatechin gallate attenuates adhesion and migration of CD8+ T cells by binding to CD11b. J Allergy Clin Immunol (2004) 1.13
Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer. Cancer Lett (2006) 1.10
Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites. Ann Surg Oncol (2013) 1.10
Sphingosine 1-phosphate transactivates c-Met as well as epidermal growth factor receptor (EGFR) in human gastric cancer cells. FEBS Lett (2004) 1.09
The expression pattern of Ku correlates with tumor radiosensitivity and disease free survival in patients with rectal carcinoma. Cancer (2002) 1.09
Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. Dis Colon Rectum (2011) 1.08
Cerebral lipiodol embolism after transcatheter arterial chemoembolization of hepatocellular carcinoma. J Comput Assist Tomogr (2005) 1.07
Pitfalls of pit pattern diagnosis in ulcerative colitis-associated dysplasia. Gastroenterology (2004) 1.07
Avoiding chest tube placement after video-assisted thoracoscopic wedge resection of the lung. Eur J Cardiothorac Surg (2004) 1.06
Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways. Eur J Cancer (2011) 1.06
Targeting Id1 and Id3 inhibits peritoneal metastasis of gastric cancer. Cancer Sci (2005) 1.05
Confined progression of cap polyposis along the anastomotic line, implicating the role of inflammatory responses in the pathogenesis. Gastrointest Endosc (2005) 1.05
The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: a comparison between direct sequencing and real-time PCR. Biochem Biophys Res Commun (2010) 1.05
Gastrointestinal stromal tumor of the retroperitoneum: CT and MR findings. Eur Radiol (2004) 1.05
Tumor location is a prognostic factor in poorly differentiated adenocarcinoma, mucinous adenocarcinoma, and signet-ring cell carcinoma of the colon. Int J Colorectal Dis (2011) 1.04
A case of paracecal hernia. Int Surg (2010) 1.03
Biotin deficiency affects the proliferation of human embryonic palatal mesenchymal cells in culture. J Nutr (2008) 1.02
Predicting the response to preoperative radiation or chemoradiation by a microarray analysis of the gene expression profiles in rectal cancer. Surg Today (2012) 1.02
Multimedia article. Lateral lymph node dissection with preoperative chemoradiation for locally advanced lower rectal cancer through a laparoscopic approach. Surg Endosc (2011) 1.02
FDG-PET after radiotherapy is a good prognostic indicator of rectal cancer. Ann Nucl Med (2002) 1.02
Gene expression signature and the prediction of ulcerative colitis-associated colorectal cancer by DNA microarray. Clin Cancer Res (2007) 1.01
A case of lung squamous cell carcinoma with metastases to the duodenum and small intestine. Int Surg (2011) 1.01
Function of Piwi, a nuclear Piwi/Argonaute protein, is independent of its slicer activity. Proc Natl Acad Sci U S A (2013) 1.00
A case report of thyroid gland metastasis associated with lung metastasis from colon cancer. Tumori (2011) 1.00
A Japanese post-marketing surveillance of cetuximab (Erbitux®) in patients with metastatic colorectal cancer. Jpn J Clin Oncol (2012) 1.00
Thrombocytosis before pre-operative chemoradiotherapy predicts poor response and shorter local recurrence-free survival in rectal cancer. Int J Colorectal Dis (2012) 0.99
Rice germline-specific Argonaute MEL1 protein binds to phasiRNAs generated from more than 700 lincRNAs. Plant J (2014) 0.98
Selective lateral pelvic lymph node dissection in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy based on pretreatment imaging. Ann Surg Oncol (2013) 0.98
The use of a lateral stabilizer increases the incidence of wound trouble following the Nuss procedure. Ann Thorac Surg (2004) 0.98
Primary malignant melanoma of the anterior mediastinum: CT and MR findings. Clin Imaging (2007) 0.98
Lysophosphatidic acid transactivates both c-Met and epidermal growth factor receptor, and induces cyclooxygenase-2 expression in human colon cancer LoVo cells. World J Gastroenterol (2005) 0.98
Prognostic impact of primary tumor resection and lymph node dissection in stage IV colorectal cancer with unresectable metastasis: a propensity score analysis in a multicenter retrospective study. Ann Surg Oncol (2014) 0.98
High-risk stage II colon cancer after curative resection. J Surg Oncol (2011) 0.97
Poorly differentiated adenocarcinoma and mucinous carcinoma of the colon and rectum show higher rates of loss of heterozygosity and loss of E-cadherin expression due to methylation of promoter region. Int J Cancer (2002) 0.97
Antitumour activity of S-1 in combination with cetuximab on human gastric cancer cell lines in vivo. Anticancer Res (2011) 0.95
Lysophospholipids transactivate HER2/neu (erbB-2) in human gastric cancer cells. Biochem Biophys Res Commun (2005) 0.95
Characterization of elevated alanine aminotransferase levels during pegylated-interferon α-2b plus ribavirin treatment for chronic hepatitis C. Hepatol Res (2011) 0.94
Treatment of colorectal carcinoids: A new paradigm. World J Gastrointest Surg (2010) 0.93
Dual mode regulation of migration by lysophosphatidic acid in human gastric cancer cells. Exp Cell Res (2004) 0.93
Locus- and domain-dependent control of DNA methylation at mouse B1 retrotransposons during male germ cell development. Genome Res (2011) 0.93
Barium enema and CT volumetry for predicting pathologic response to preoperative chemoradiotherapy in rectal cancer patients. Dis Colon Rectum (2014) 0.92
Colorectal cancer and hypercoagulability. Surg Today (2013) 0.92
Formalin application in the treatment of chronic radiation-induced hemorrhagic proctitis induces acute deterioration of mucosal blood flow. Dis Colon Rectum (2006) 0.92
Orotate phosphoribosyltransferase expression level in tumors is a potential determinant of the efficacy of 5-fluorouracil. Biochem Biophys Res Commun (2007) 0.92
Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions. Oncotarget (2014) 0.92
New material for reconstruction of the anterior chest wall, including the sternum. J Thorac Cardiovasc Surg (2003) 0.92
Values of water-soluble vitamins in blood and urine of Japanese young men and women consuming a semi-purified diet based on the Japanese Dietary Reference Intakes. J Nutr Sci Vitaminol (Tokyo) (2005) 0.91
Folylpolyglutamate synthase and gamma-glutamyl hydrolase regulate leucovorin-enhanced 5-fluorouracil anticancer activity. Biochem Biophys Res Commun (2007) 0.91
Gene expression signature and the prediction of lymph node metastasis in colorectal cancer by DNA microarray. Dis Colon Rectum (2009) 0.91
Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity. Cancer Sci (2004) 0.91
Cytomegalovirus infection in ulcerative colitis. Scand J Gastroenterol (2006) 0.91
Detection of desmoplastic reaction in biopsy specimens is useful for predicting the depth of invasion of early colorectal cancer: a Japanese collaborative study. J Gastroenterol (2010) 0.91
Prospective surveillance effectively reduced rates of surgical site infection associated with elective colorectal surgery at a university hospital in Japan. Infect Control Hosp Epidemiol (2006) 0.91
Nomogram prediction of metachronous colorectal neoplasms in patients with colorectal cancer. Ann Surg (2015) 0.91
Endoscopic and chromoendoscopic atlas featuring dysplastic lesions in surveillance colonoscopy for patients with long-standing ulcerative colitis. Inflamm Bowel Dis (2008) 0.91
Laparoscopic surgery for ulcerative colitis: a review of the literature. Surg Today (2014) 0.90
Reduced p16 expression correlates with lymphatic invasion in colorectal cancers. Hepatogastroenterology (2003) 0.90
Hemophagocytic syndrome caused by fulminant ulcerative colitis and cytomegalovirus infection: report of a case. Dis Colon Rectum (2004) 0.90
Epigallocatechin gallate induces apoptosis of monocytes. J Allergy Clin Immunol (2005) 0.90
Laparoscopic resection of a gastrointestinal stromal tumor of the lower rectum in a patient with coronary artery disease following long-term neoadjuvant imatinib treatment and anticoagulation therapy. World J Surg Oncol (2014) 0.90
The preoperative platelet to lymphocyte ratio is a prognostic marker in patients with stage II colorectal cancer. Int J Colorectal Dis (2015) 0.90
Anatomy of the inferior mesenteric artery evaluated using 3-dimensional CT angiography. Dis Colon Rectum (2015) 0.90